… We hypothesized that the association between IgM anti-PC and the risk of CV outcome is
different in the presence of CV risk factors. We therefore further performed analyses within the …

… could be related to the complexity of the LDL-oxidation process where antigens exposed
could vary to some extent, and there may also be differences in methods used for antibody …

… with the clinical outcomes. Potential immunomodulatory … antibody to target the root
causes of the inflammation and treat patients with early RA, thereby atherosclerosis and CVD…

… We also divided patients into inflamed C-reactive protein (CRP) > 5·6 mg/ml and non-inflamed
CRP. Antibody levels were determined by in-house enzyme-linked immunosorbent assay. …

Atherosclerosis and its main consequence, cardiovascular disease (CVD) are nowadays
regarded as chronic inflammatory disease conditions, and CVD is the main cause of death in …

… The antibody levels were used for cases vs controls and cross-disease analysis. Statistical …
for each antibody. The correlation between antibody level and cardiovascular score (CV) was …

… phosphocholine (POVPC); the antibody binding is tested for all known antigens that expose
PC. Capsular polysaccharide (C-PS), POVPC conjugated with bovine serum albumin (BSA), …

… mice that a specific clone of IgM autoantibodies against phosphorylcholine, termed E06 or
T15 … IgM phosphorylcholine antibodies are associated with an increased risk of cardiovascular …

… Abs against phosphorylcholine (anti-PC) and Abs against malondialdehyde (anti-MDA) may
be protective in chronic inflammation, like atherosclerosis and cardiovascular disease. It is …

… anti-phospholipid autoantibody levels in patients with antiphospholipid syndrome, …
cardiovascular diseases. However, the underlying mechanisms of anti-phospholipid autoantibodies …